Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
RUGGERI, Annalisa
VOLT, Fernanda
LOCATELLI, Franco
MICHEL, Gerard
HEREDIA, Cristina Diaz de
ABECASIS, Manuel
ZECCA, Marco
VORA, Ajay
YAKOUBEN, Karima
O'BRIEN, Tracey A.
Citação
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, v.23, n.1, p.96-102, 2017
Resumo
Infant acute leukemia still has a poor prognosis, and allogeneic hematopoietic stem cell transplantation is indicated in selected patients. Umbilical cord blood (UCB) is an attractive cell source for this population because of the low risk of chronic graft-versus-host disease (GVHD), the strong graft-versus-leukemia effect, and prompt donor availability. This retrospective, registry-based study reported UCB transplantation (UCBT) outcomes in 252 children with acute lymphoblastic leukemia (ALL; n = 157) or acute myelogenous leukemia (AML; n = 95) diagnosed before 1 year of age who received a single-unit UCBT after myeloablative conditioning between 1996 and 2012 in European Society for Blood and Marrow Transplantation centers. Median age at UCBT was 1.1 years, and median follow-up was 42 months. Most patients (57%) received a graft with 1 HLA disparity and were transplanted in first complete remission (CR; 55%). Cumulative incidence function (CIF) of day 100 acute GVHD (grades II to IV) was 40% 3% and of 4-year chronic GVHD was 13% 2%. CIF of 1-year transplant-related mortality was 23% 3% and of 4-year relapse was 27% 3%. Leukemia-free-survival (LFS) at 4 years was 50% 3%; it was 40% and 66% for those transplanted for ALL and AML, respectively (P = .001). LFS was better for patients transplanted in first CR, regardless of diagnosis. In multivariate model, diagnosis of ALL (P = .001), advanced disease status at UCBT (<.001), age at diagnosis younger than 3 months (P = .012), and date of transplant before 2004 were independently associated with worse LFS. UCBT is a suitable option for patients diagnosed with infant acute leukemia who achieve CR. In this cohort, patients with AML had better survival than those with ALL. 2017 American Society for Blood and Marrow Transplantation.
Palavras-chave
Cord blood transplantation, Infant, Acute leukemia, MLL-rearranged leukemia
Referências
- Aladjidi N, 2003, J CLIN ONCOL, V21, P4377, DOI 10.1200/JCO.2003.11.066
- Biondi A, 2000, BLOOD, V96, P24
- Dreyer ZE, 2011, J CLIN ONCOL, V29, P214, DOI 10.1200/JCO.2009.26.8938
- Driessen EMC, 2016, LEUKEMIA, V30, P1184, DOI 10.1038/leu.2015.246
- Eapen M, 2006, J CLIN ONCOL, V24, P145, DOI 10.1200/JCO.2005.02.4612
- Eapen M, 2007, LANCET, V369, P1947, DOI 10.1016/S0140-6736(07)60915-5
- Fagioli F, 2008, J PEDIAT HEMATOL ONC, V30, P575, DOI 10.1097/MPH.0b013e31816e2342
- Flowers MED, 1999, HEMATOL ONCOL CLIN N, V13, P1091, DOI 10.1016/S0889-8588(05)70111-8
- Foresto SA, 2015, PEDIATR BLOOD CANCER, V62, P1664, DOI 10.1002/pbc.25517
- Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441
- Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972
- Imamura T, 2012, BRIT J HAEMATOL, V159, P204, DOI 10.1111/bjh.12030
- Isoyama K, 2010, BONE MARROW TRANSPL, V45, P69, DOI 10.1038/bmt.2009.93
- Koh K, 2015, LEUKEMIA, V29, P290, DOI 10.1038/leu.2014.172
- Kotecha RS, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.17
- Masetti R, 2014, HAEMATOLOGICA, V99, pE127, DOI 10.3324/haematol.2014.106526
- Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
- Michel G, 2016, LEUKEMIA, V30, P1180, DOI 10.1038/leu.2015.243
- Nakayama H, 2014, INT J HEMATOL, V100, P171, DOI 10.1007/s12185-014-1616-9
- Pession A, 2005, LEUKEMIA, V19, P2043, DOI 10.1038/sj.leu.2403869
- Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X
- Pollard JA, 2016, J CLIN ONCOL, V34, P747, DOI 10.1200/JCO.2015.62.6846
- Przepiorka D, 1995, BONE MARROW TRANSPL, V16, P737
- Rocha V, 2000, NEW ENGL J MED, V342, P1846, DOI 10.1056/NEJM200006223422501
- Rocha V, 2004, NEW ENGL J MED, V351, P2276, DOI 10.1056/NEJMoa041469
- Sander A, 2010, LEUKEMIA, V24, P1422, DOI 10.1038/leu.2010.127
- Sanders JE, 2005, BLOOD, V105, P3749, DOI 10.1182/blood-2004-08-3312
- Schlegel P, 2014, HAEMATOLOGICA, V99, P1212, DOI 10.3324/haematol.2013.100073
- Sison EAR, 2013, HEMATOL-AM SOC HEMAT, P601
- Tomizawa D, 2007, LEUKEMIA, V21, P2258, DOI 10.1038/sj.leu.2404903
- Tsukimoto I, 2009, J CLIN ONCOL, V27, P4007, DOI 10.1200/JCO.2008.18.7948
- Webb DKH, 1999, LEUKEMIA, V13, P25, DOI 10.1038/sj.leu.2401254